• Explore /
  • Poster
  • / Regorafenib (REGO) plus FOLFIRINOX as frontline treatment in patients (pts) with RAS-mutated metastatic colorectal cancer (mCRC): A phase I/II, dose-escalation and dose-expansion study.

Regorafenib (REGO) plus FOLFIRINOX as frontline treatment in patients (pts) with RAS-mutated metastatic colorectal cancer (mCRC): A phase I/II, dose-escalation and dose-expansion study.

Abstract Poster

Authors

null

Antoine Adenis

Institut du Cancer de Montpellier, Montpellier, France

Antoine Adenis , François Ghiringhelli , Ludovic Gauthier , Thibault Mazard , Ludovic Evesque , Pierre-Luc Etienne , Alexandre Evrard , Patrick Chalbos , Jean-Pierre Bleuse , Diego Tosi , Sophie Gourgou , Marc Ychou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT03828799

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3561)

DOI

10.1200/JCO.2022.40.16_suppl.3561

Abstract #

3561

Poster Bd #

355

Abstract Disclosures

Similar Posters

First Author: Patrick M Boland

First Author: Hideaki Bando

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Phase II study of the safety and efficacy of discontinuing pegfilgrastim for pancreatic adenocarcinoma treated with FOLFIRINOX.

Phase II study of the safety and efficacy of discontinuing pegfilgrastim for pancreatic adenocarcinoma treated with FOLFIRINOX.

First Author: Masahiro Yanagi

First Author: Hideaki Bando